STOCKHOLM--(BUSINESS WIRE)--Regulatory News:
Wilson Therapeutics AB (publ) (STO:WTX), announces that preliminary data from the company’s ongoing Phase II clinical trial for Decuprate® (bis-choline tetrathiomolybdate; WTX101) in Wilson Disease will be presented today at the 20th International Congress of Parkinson´s Disease and Movement Disorders, taking place in Berlin, Germany, June 19-23. The poster presentation of the data will be provided by Prof. Anna Czlonkowska. The underlying data have previously been presented at the Congress of the European Academy of Neurology on May 30.
